Roche says can start to talk about curing cancer

	Tweet

Recent advances in treatment mean it is possible to start talking about curing some types of cancer, the world’s biggest maker of cancer drugs said on Thursday.

Swiss-based Roche argued the use of modern medicines, such as breast cancer drug Herceptin, at an early stage of disease was transforming the outlook for patients.

“There is a quantum leap here,” William Burns, Roche’s head of pharmaceuticals, told analysts in London, after the company reported a surge in first-half profits on the back of strong cancer drug sales. 

"The word ‘cure’ can start to come into the discussions on non-Hodgkin’s lymphoma, for some people, and for breast cancer for ladies with early-stage HER2-positive (disease).”

Roche’s drug MabThera, or Rituxan, is used to treat non-Hodgkin’s lymphoma, a type of cancer that affects the white blood cells, while Herceptin has been shown to cut cancer recurrence in women with aggressive HER2 breast cancer.

Avastin, which works by starving tumors of blood supply, is another medicine from Roche’s partnership with majority-owned Genentech that is revolutionizing treatment.

All are examples of so-called “targeted therapies” that extend lives with far fewer toxic side effects than standard chemotherapy for certain groups of patients.

However, the high price of targeted therapies—running to tens of thousands of dollars a year—has been criticized by patient groups and payers, prompting talk of a backlash, similar to the controversy over AIDS drug prices in the 1990s.

But Burns said cancer medicines still accounted for only a tiny fraction of spending, with oncology therapies making up just 1/2 percent of healthcare expenditure in Europe, according to recent study by Sweden’s Karolinska Institute.

Newer treatments were highly cost-effective, he said, adding that governments should look to looming savings on medicines about to go off patent to help pay for them.

“There are billions of dollars of pharmaceuticals that are going off patent. That can provide oxygen to the system before we need to print a new euro or pound or dollar,” he said.

The recent advances in fighting cancer have made oncology the fastest-growing section of the pharmaceuticals market, tempting many more companies into the field.

Rivals include industry giants like Pfizer and GlaxoSmithKline, which has a similar drug to Herceptin called Tykerb that is now awaiting regulatory approval. But Burns said it would be several years before Glaxo had sufficient clinical trial data to make Tykerb a significant competitor.

Roche’s sales of cancer medicines totaled 10.2 billion Swiss francs ($8.18 billion) last year and sales climbed 48 percent in the first half of 2006.

RELATED STORIES:
U.S. cancer rates continue their decline: report   Working with poultry linked to certain cancers   Penn Study on Silencing of Tumor Suppressor Gene Suggests New Target for Lymphoma   AACR to Host Teleconference on Metastasis   Some tumors contain factors that may block metastasis   Studies Investigate Health Care at the End of Life   Workers in No-Smoking Restaurants Show Lower Carcinogen Levels   The future of personalized cancer treatment: An entirely new direction for RNAi delivery   The role of genes in the development of non-Hodgkin’s lymphomas   New Algorithm Matches Tumor Cells to Best Anticancer Treatments   2008 Cancer Incidence and Mortality Report   Black Raspberries May Slow Growth of Colon, Other Cancers   Late-Breaking Science and Clinical Trials   Brits denied new targeted bowel cancer drugs   Reversing cell division has implications for the treatment of cancer   FISH-ing for Links Between Cancer and Aging   New Hope for Cancer Comes Straight from the Heart   Targeted Virus Compels Cancer Cells to Eat Themselves   Calorie restriction limits and obesity fuels development of epithelial cancers   High ‘good’ cholesterol tied to lower cancer risk   Loss of Caspase-8 Makes Neuroblastoma More Aggressive   How cancer cells stay young and aggressive

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]